Metabolic Surgery Progenitor of Effective Therapy for Atherosclerotic Cardiovascular Disease, Cancer, Type 2 Diabetes, and Obesity

"Metabolic Surgery Progenitor of Effective Therapy for Atherosclerotic Cardiovascular Disease, Cancer, Type 2 Diabetes, and Obesity"

Henry Buchwald’s article, “Metabolic Surgery: Progenitor of Effective Therapy for Atherosclerotic Cardiovascular Disease, Cancer, Type 2 Diabetes, and Obesity,” published in the Annals of Surgery (Volume 281, Number 5, May 2025), offers a comprehensive exploration of metabolic surgery’s role as a pioneering force in modern medicine. Buchwald defines metabolic surgery as the operative manipulation of normal organs to achieve beneficial metabolic outcomes, a concept formalized in 1978 but with roots tracing back to 1889 with oophorectomy for breast cancer. The article focuses on four key conditions-atherosclerotic cardiovascular disease (ASCVD), cancer, type 2 diabetes, and obesity-demonstrating how surgical interventions have elucidated metabolic pathways, paving the way for nonsurgical therapies. For ASCVD, the Program on the Surgical Control of the Hyperlipidemias (POSCH) trial showcased partial ileal bypass reducing cholesterol and mortality, influencing statin development. In cancer, oophorectomy’s hormonal insights prefigured drugs like tamoxifen.

For type 2 diabetes and obesity, bariatric surgery’s metabolic effects, particularly via GLP-1 elevation, inspired drugs like Ozempic and Wegovy. Buchwald lists 22 procedures and suggests future applications (e.g., traumatic brain injury), arguing that metabolic surgery transforms surgery into a metabolic discipline driving translational research cyclically.

Bariatric surgery acts as a metabolic catalyst, inducing rapid, durable diabetes remission through neurohormonal pathways like GLP-1 upregulation .

- GLP-1 agonists replicate aspects of surgery’s metabolic benefits without invasive intervention, though they lack the multifaceted physiological effects of surgery .-  Metabolic surgery remains the **benchmark** for diabetes resolution, while pharmacotherapy offers a less burdensome alternative for noncandidates .

 A critical strength lies in the article’s interdisciplinary synthesis, linking metabolic surgery to mechanistic insights across multiple pathologies. By detailing longitudinal clinical trials (e.g., 25-year follow-up of POSCH participants) and molecular pathways (e.g., GLP-1-mediated insulin secretion), the work underscores the reproducibility and biological plausibility of metabolic interventions . Furthermore, the discussion of emerging applications-such as carotid sinus stimulation for hypertension and vagal nerve modulation for depression-highlights the field’s adaptability and potential to address unmet clinical needs.